Anthropic’s Rise Has Been Stunning, How Big Can It Get?
A year ago, Anthropic was a specialist name known mostly within AI research circles. Today, the company behind Claude is scaling so quickly that veteran investors openly call its trajectory “almost without precedent.”
Its sharp focus on enterprise AI, and its increasingly intertwined relationship with Microsoft, has made one comparison hard to ignore: is Anthropic quietly positioning itself the way Microsoft did in the early PC era?
» Read more about: Anthropic’s Rise Has Been Stunning, How Big Can It Get? »
Read More
Will Prediction Markets Disrupt DraftKings?
DraftKings and FanDuel have long dominated U.S. online sports betting, thanks to their early entry via daily fantasy sports.
That first-mover advantage, combined with cutting-edge technology and deep brand recognition, let both companies capture the lion’s share of the market as sports betting rolled out state by state.
But a new kind of competitor is emerging that could rewrite the rules of online wagering.
» Read more about: Will Prediction Markets Disrupt DraftKings? »
Read More
1 Stock That Is The Power Behind Nuclear Revival?
Cameco isn’t just a miner. It’s the world’s largest publicly traded uranium producer, but its reach extends far beyond extraction.
The company refines uranium, manufactures reactor fuel rods, and even owns 49% of Westinghouse Electric, one of the few firms that designs and builds nuclear reactors. This level of integration is rare in the commodity world,
» Read more about: 1 Stock That Is The Power Behind Nuclear Revival? »
Read More
Beyond Meat’s Shocking Rebound
Few investors saw it coming. After spending most of the year circling the drain, Beyond Meat suddenly roared back to life last week, climbing more than 5x from its October lows.
At one point, the stock traded below $1, a price level that had many wondering if bankruptcy was next. Then came an eruption of retail enthusiasm that sent shares briefly rocketing toward $8.
» Read more about: Beyond Meat’s Shocking Rebound »
Read More
1 Infrastructure Specialist That’s Suddenly on Sale
Once investors saw how fast CoreWeave revenues were accelerating, hesitation disappeared. Shares didn’t just climb, they exploded, rising more than 4x in a matter of weeks.
That kind of surge rarely lasts forever, and over the past month CoreWeave has given back roughly 35%. The pullback has left investors wondering whether something fundamental has changed or whether this is simply the kind of temporary reset that follows massive gains.
» Read more about: 1 Infrastructure Specialist That’s Suddenly on Sale »
Read MoreThe Burst
Why Rivian’s Stock Is Suddenly Popping
Shares have ripped higher recently, and the reason has less to do with flashy announcements and more to do with something far more fundamental, Rivian is fixing the hardest part of the EV business.
On the surface, Rivian Automotive looked like it was catching its breath in 2025. No new models. No headline-grabbing unveilings.
» Read more about: Why Rivian’s Stock Is Suddenly Popping »
Read MoreThe Spotlight
Billionaire Dumps Popular AI Stock
In the second quarter, billionaire Steven Cohen exited its entire position in SoundHound AI, a company once touted as one of the purest ways to invest in voice-driven artificial intelligence.
The move came after SoundHound’s stock had surged more than 3x in a year as investors piled into anything labeled “AI.”
So why would one of Wall Street’s most sophisticated investors bail out just as the hype peaked?
» Read more about: Billionaire Dumps Popular AI Stock »
Read MoreThe Daily
Is Pfizer Stock Underperforming the Dow?
Founded 170 years ago and currently headquartered in New York, Pfizer Inc. (PFE) is a global biopharmaceutical powerhouse with a presence in over 125 countries. At its core, Pfizer researches, develops, manufactures and markets medicines and vaccines across a wide spectrum: from oncology to immunology, internal medicine, rare diseases, and preventive vaccines.
With a market capitalization of roughly $146 billion,
» Read more about: Is Pfizer Stock Underperforming the Dow? »